Medios AG (ILM1) - Total Liabilities
Based on the latest financial reports, Medios AG (ILM1) has total liabilities worth €388.82 Million EUR (≈ $454.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Medios AG to assess how effectively this company generates cash.
Medios AG - Total Liabilities Trend (2009–2025)
This chart illustrates how Medios AG's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Medios AG to evaluate the company's liquid asset resilience ratio.
Medios AG Competitors by Total Liabilities
The table below lists competitors of Medios AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AerSale Corp
NASDAQ:ASLE
|
USA | $216.04 Million |
|
Xinjiang Youhao Group Co Ltd
SHG:600778
|
China | CN¥3.15 Billion |
|
Yunnan Bowin Technology Industry Co Ltd
SHG:600883
|
China | CN¥60.19 Million |
|
United Malacca Bhd
KLSE:2593
|
Malaysia | RM319.41 Million |
|
CellaVision AB
ST:CEVI
|
Sweden | Skr207.31 Million |
|
K&F Growth Acquisition Corp. II Class A Ordinary shares
NASDAQ:KFII
|
USA | $10.15 Million |
|
Know Labs Inc.
NYSE MKT:KNW
|
USA | $5.28 Million |
|
Canada Nickel Company Inc
V:CNC
|
Canada | CA$60.31 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Medios AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ILM1 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.45 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medios AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medios AG (2009–2025)
The table below shows the annual total liabilities of Medios AG from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €388.82 Million ≈ $454.57 Million |
-8.33% |
| 2024-12-31 | €424.17 Million ≈ $495.89 Million |
+236.78% |
| 2023-12-31 | €125.95 Million ≈ $147.24 Million |
-1.54% |
| 2022-12-31 | €127.91 Million ≈ $149.54 Million |
-1.59% |
| 2021-12-31 | €129.98 Million ≈ $151.96 Million |
+149.42% |
| 2020-12-31 | €52.11 Million ≈ $60.92 Million |
+49.14% |
| 2019-12-31 | €34.94 Million ≈ $40.85 Million |
+25.15% |
| 2018-12-31 | €27.92 Million ≈ $32.64 Million |
+74.17% |
| 2017-12-31 | €16.03 Million ≈ $18.74 Million |
+16.48% |
| 2016-12-31 | €13.76 Million ≈ $16.09 Million |
+7321.68% |
| 2015-12-31 | €185.43K ≈ $216.79K |
+106.53% |
| 2014-12-31 | €89.78K ≈ $104.97K |
-60.37% |
| 2013-12-31 | €226.54K ≈ $264.85K |
-15.52% |
| 2012-12-31 | €268.14K ≈ $313.49K |
-4.48% |
| 2011-12-31 | €280.72K ≈ $328.20K |
-45.84% |
| 2010-12-31 | €518.32K ≈ $605.98K |
-117.75% |
| 2009-12-31 | €-2.92 Million ≈ $-3.41 Million |
-- |
About Medios AG
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. The company operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic preparations, antibody therapies, a… Read more